Can we predict blood cancer in ovarian cancer survivors?
NCT ID NCT06295965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 2,000 people who have had ovarian or other solid cancers to learn why some later develop blood cancers like leukemia. Researchers will look at genetic changes in blood cells and treatment history to identify risk factors. No new treatments are being tested—the goal is to gather knowledge for future prevention or early detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which cancer survivors are at higher risk for blood cancers, leading to better monitoring or prevention strategies.
- What could go wrong
- This is an observational study, not testing a treatment. It may not find clear risk factors, and results may take years to impact patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a targeted drug revive blood cell production in a Pre-Leukemic condition?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?